This review summarizes current and near-future medical therapies for acute coronary syndromes, including thrombolytic, antithrombin, and antiplatelet agents, as well as controversies between medical and interventional strategies.
Answers are grounded in this paper and cite their sources.
Updates ACS pharmacotherapy options for clinicians; leaves open optimal medical-interventional integration pending new trials.
The medical treatment of acute coronary syndromes with thrombolytic, antithrombin, and antiplatelet agents is a major area of research and a vast topic for clinical review. This review summarizes important recent findings on the background of existing pathological and clinical knowledge to provide an understanding of the basis of current therapy and the new therapies that are likely to be introduced in the near future. Current controversies regarding the management of these conditions and the choice between medical, interventional, and combined strategies in different situations are also discussed.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: